Relief Therapeutics Holding SA

RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders